Company continues to supply high-quality
medicines to approximately 1 billion patients annually
Report chronicles Viatris' commitment to
providing access to healthcare and building healthier
communities
Impactful story highlights include "Empathy in
Africa: Bridging the Healthcare
Divide" – a powerful new documentary short that showcases
Viatris' impact
PITTSBURGH, May 21, 2024
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global
healthcare company, today published its 2023 Sustainability
Report: Building Sustainable Access at Scale. The report highlights
its actions and initiatives across multiple areas of focus in
support of the Company's efforts to continue to be a model for
sustainable access to medicine and to make a difference in the
communities it serves.
"This year's report delivers many examples of the important
efforts occurring across Viatris and the collaboration required to
supply high-quality medicines to approximately 1 billion patients
annually," said Lara Ramsburg,
Chief Corporate Affairs Officer, Viatris. "Everyone at Viatris
plays a part in building sustainable access to medicine, supporting
healthcare systems and helping to advance our overall
sustainability performance. Every day, no matter their roles or
responsibilities, each team member performs essential work across
multiple functions and geographies that collectively supports our
progress. The knowledge that needs are great, and that our actions
matter, is a powerful motivation."
In 2023, Viatris colleagues remained committed to building
sustainable access at scale. The Report presents work, stories and
progress supporting four main areas: Access and Global
Health; Our People; Environment; and Community.
Highlights include:
- Access and Global Health: Investing in facilities around
the world, including in low- and lower-middle-income countries
(LMICs), to bolster Viatris' global supply chain network and uphold
a reliable supply of medicines across the world. Doing so, the
Company sold more than 80 billion doses of medicine across more
than 165 countries and territories and reached more than 90% of
LMICs with its medicines.
- Our People: Launched Elevate, its new wellbeing program
for all colleagues. Elevate helps define the Company's holistic
approach to wellbeing, centered around three principles: Health,
Purpose and Growth.
- Environment: Working to ensure stable access to
high-quality medicines while minimizing the Company's environmental
impact, including the areas of greenhouse gas emission (GHG)
reductions, energy use, water withdrawal and air emissions. Since
2020, Viatris accomplished a 3.7% reduction of its scope 1 and 2
GHG emissions compared to baseline.1
- Community: Building healthier communities by supporting
local efforts to strengthen healthcare, education and communities.
In 2023, Viatris donated to multiple global humanitarian relief
partners via corporate philanthropy donations and donated more than
300 million doses of its medicines for humanitarian needs through
corporate partners globally.
"At Viatris, we take pride in our work to advance more
sustainable operations and responsible practices in delivering
high-quality medicines and health solutions to people globally,"
said Lina Andersson, Head of Global
Sustainability, Viatris. "We have worked diligently and will
continue to do so, to be considered a trusted partner as we support
progress in closing gaps to equal access to care, build more
resilient healthcare systems and uphold a reliable global supply of
medicines."
The recently launched documentary short, "Empathy in
Africa: Bridging the Healthcare
Divide," highlights the important work Viatris is supporting to
build access to healthcare in South
Africa. The film chronicles the development of The Rhiza
Babuyile Clinic, a critical health clinic in the Diepsloot Township
of Johannesburg, South Africa,
that is known for its challenging infrastructure, overcrowding and
limited access to basic resources. Co-funded by Viatris, the clinic
is Diepsloot's first private brick and mortar healthcare facility,
offering basic care and pediatrics and reducing healthcare
inequities for the people of the township. The film is available to
be streamed on the WaterBear Network now and on Apple TV on
May 23.
Viatris is dedicated to transparent annual reporting on
environmental, social and governance matters, continuously working
to further enhance its disclosures through its 2023 Sustainability
Report. Click here to find further information and additional
examples of the important work occurring across the Company.
Forward-Looking Statements
This press release includes
statements that constitute "forward-looking statements." These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements may include, without limitation,
statements about our sustainability goals, initiatives and
investments, including with respect to access and global health,
our people, environment and community. Forward-looking statements
may often be identified by the use of words such as "will," "may,"
"could," "should," "would," "project," "believe," "anticipate,"
"expect," "plan," "estimate," "forecast," "potential," "pipeline,"
"intend," "continue," "target," "seek" and variations of these
words or comparable words. Because forward-looking statements
inherently involve risks and uncertainties, actual future results
may differ materially from those expressed or implied by such
forward- looking statements. Factors that could cause or contribute
to such differences include, but are not limited to: our ability to
impact and effectively execute on our key sustainability areas
encompassing access and global health including reliable supply and
high-quality medicine; our people; environmental impact; and
governance and ethical practices; sustainability-related disclosure
frameworks and reporting standards which may change from time to
time, including our ability to collect, measure, quantify, and
report on our sustainability-related information, which may be
subject to various global reporting standards; the possibility that
the Company may not realize the intended benefits of, or achieve
the intended goals or outlooks with respect to, its strategic
initiatives (including divestitures, acquisitions, or other
potential transactions) or move up the value chain by focusing on
more complex and innovative products to build a more durable higher
margin portfolio; the possibility that the Company may be unable to
achieve intended or expected benefits, goals, outlooks, synergies,
growth opportunities and operating efficiencies in connection with
divestitures, acquisitions, other transactions, or restructuring
programs, within the expected timeframes or at all; the Company's
failure to achieve expected or targeted future financial and
operating performance and results; the potential impact of public
health outbreaks, epidemics and pandemics; actions and decisions of
healthcare and pharmaceutical regulators; changes in relevant laws
and regulations and policies and/or the application or
implementation thereof, including but not limited to tax,
healthcare, applicable environmental laws, and pharmaceutical laws,
regulations and policies globally (including the impact of recent
and potential tax reform in the U.S. and pharmaceutical product
pricing policies in China); any
regulatory, legal or other impediments to the Company's ability to
bring new products to market, including but not limited to "at-risk
launches;" success of clinical trials and the Company's or its
partners' ability to execute on new product opportunities and
develop, manufacture and commercialize products; any changes in or
difficulties with the Company's manufacturing facilities, including
with respect to inspections, remediation and restructuring
activities, supply chain or inventory or the ability to meet
anticipated demand; the scope, timing and outcome of any ongoing
legal proceedings, including government inquiries or
investigations, and the impact of any such proceedings on the
Company; risks associated with having significant operations
globally; the ability to protect intellectual property and preserve
intellectual property rights; changes in third-party relationships;
the effect of any changes in the Company's or its partners'
customer and supplier relationships and customer purchasing
patterns, including customer loss and business disruption being
greater than expected following an acquisition or divestiture; the
impacts of competition, including decreases in sales or revenues as
a result of the loss of market exclusivity for certain products;
changes in the economic and financial conditions of the Company or
its partners; uncertainties regarding future demand, pricing and
reimbursement for the Company's products; uncertainties and matters
beyond the control of management, including but not limited to
general political and economic conditions, inflation rates and
global exchange rates; and the other risks described in
Viatris' filings with the Securities and Exchange Commission (SEC).
Viatris routinely uses its website as a means of disclosing
material information to the public in a broad, non-exclusionary
manner for purposes of the SEC's Regulation Fair Disclosure (Reg
FD). Viatris undertakes no obligation to update these statements
for revisions or changes after the date of this release other than
as required by law.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global
healthcare company uniquely positioned to bridge the traditional
divide between generics and brands, combining the best of both to
more holistically address healthcare needs globally. With a mission
to empower people worldwide to live healthier at every stage of
life, we provide access at scale, currently supplying high-quality
medicines to approximately 1 billion patients around the world
annually and touching all of life's moments, from birth to the end
of life, acute conditions to chronic diseases. With our
exceptionally extensive and diverse portfolio of medicines, a
one-of-a-kind global supply chain designed to reach more people
when and where they need them, and the scientific expertise to
address some of the world's most enduring health challenges, access
takes on deep meaning at Viatris. We are headquartered in the U.S.,
with global centers in Pittsburgh,
Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
LinkedIn, Instagram, YouTube and X (formerly
Twitter).
1 Per Dec. 31, 2023,
and not taking into account divestitures.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viatris-publishes-2023-sustainability-report-building-sustainable-access-at-scale-302150685.html
SOURCE Viatris Inc.